Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Eva M M Verkolf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-1294-0090; OpenAlex author ID A5092820538. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 11

  1. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  2. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  3. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  6. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  7. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  8. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  9. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  10. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  11. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. First author DOI 10.1186/s12885-023-11141-5↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Esther N. Dekker · 8 shared papers, 2023–2026 · strength 1.52
  2. Bas Groot Koerkamp · 8 shared papers, 2023–2026 · strength 1.52
  3. Marc G. Besselink · 8 shared papers, 2023–2026 · strength 1.52
  4. Roeland F. de Wilde · 6 shared papers, 2024–2026 · strength 1.25
  5. Matthew H. G. Katz · 4 shared papers, 2024–2026 · strength 0.87
  6. Amer H. Zureikat · 4 shared papers, 2024–2026 · strength 0.87
  7. Laura R. Prakash · 4 shared papers, 2024–2026 · strength 0.87
  8. Ching-Wei David Tzeng · 4 shared papers, 2024–2026 · strength 0.87
  9. Alice Chia-Chi Wei · 4 shared papers, 2024–2026 · strength 0.87
  10. Eileen Mary O'Reilly · 4 shared papers, 2024–2026 · strength 0.78
  11. Quisette P. Janssen · 4 shared papers, 2024–2026 · strength 0.76
  12. Jacob L. van Dam · 4 shared papers, 2023–2026 · strength 0.69
  13. Marjolein Y.V. Homs · 4 shared papers, 2023–2025 · strength 0.66
  14. Casper H.J. van Eijck · 4 shared papers, 2023–2025 · strength 0.61
  15. Alessandro Paniccia · 3 shared papers, 2024–2026 · strength 0.61
  16. Judith de Vos‐Geelen · 3 shared papers, 2023–2025 · strength 0.48
  17. Ignace H. J. T. de Hingh · 3 shared papers, 2023–2025 · strength 0.48
  18. Bert A. Bonsing · 3 shared papers, 2023–2025 · strength 0.48
  19. Johanna W. Wilmink · 3 shared papers, 2023–2025 · strength 0.45
  20. Rutger T. Theijse · 2 shared papers, 2024–2025 · strength 0.35
  21. Geertjan van Tienhoven · 2 shared papers, 2023–2025 · strength 0.28
  22. Marion B.M. van der Kolk · 2 shared papers, 2023–2025 · strength 0.28
  23. Brigitte C.M. Haberkorn · 2 shared papers, 2023–2025 · strength 0.28
  24. Hjalmar C. van Santvoort · 2 shared papers, 2023–2025 · strength 0.28
  25. Laura R Prakasha · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.